Wirth-Scheibenbogen hypothesis: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) m (Text replacement - "|last3=" to " | last3 = ") |
Notjusttired (talk | contribs) m (Text replacement - "|author-link5=" to " | authorlink5 = ") |
||
| Line 16: | Line 16: | ||
*2021, Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref name="Wirth2021a">{{Cite journal|last=Wirth| first = Klaus J.|author-link=Klaus Wirth | last2 = Scheibenbogen | first2=Carmen|author-link2=Carmen Scheibenbogen | date = 2021-04-21|title=Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|url=https://doi.org/10.1186/s12967-021-02833-2|journal=Journal of Translational Medicine|volume=19|issue=1|pages=162|doi=10.1186/s12967-021-02833-2|issn=1479-5876|pmc=PMC8058748|pmid=33882940}}</ref> - [https://doi.org/10.1186/s12967-021-02833-2 (Full text)] | *2021, Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref name="Wirth2021a">{{Cite journal|last=Wirth| first = Klaus J.|author-link=Klaus Wirth | last2 = Scheibenbogen | first2=Carmen|author-link2=Carmen Scheibenbogen | date = 2021-04-21|title=Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|url=https://doi.org/10.1186/s12967-021-02833-2|journal=Journal of Translational Medicine|volume=19|issue=1|pages=162|doi=10.1186/s12967-021-02833-2|issn=1479-5876|pmc=PMC8058748|pmid=33882940}}</ref> - [https://doi.org/10.1186/s12967-021-02833-2 (Full text)] | ||
*2021, Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study<ref name="Scheibenbogen2021a">{{Cite journal|last=Scheibenbogen | first = Carmen|author-link=Carmen Scheibenbogen | last2 = Sotzny | first2 = Franziska|author-link2=Franziska Sotzny | last3 = Hartwig| first3 = Jelka|author-link3= | last4 = Bauer | first4=Sandra | authorlink4 = Sandra Bauer | last5 = Freitag | first5 = Helma| | *2021, Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study<ref name="Scheibenbogen2021a">{{Cite journal|last=Scheibenbogen | first = Carmen|author-link=Carmen Scheibenbogen | last2 = Sotzny | first2 = Franziska|author-link2=Franziska Sotzny | last3 = Hartwig| first3 = Jelka|author-link3= | last4 = Bauer | first4=Sandra | authorlink4 = Sandra Bauer | last5 = Freitag | first5 = Helma | authorlink5 = Helma Freitag|last6 = Wittke | first6 = Kirsten | authorlink6 = | last7 = Doehner | first7=Wolfram | last8 = Scherbakov | first8 = Nadja|last9 = Loebel | first9 = Madlen | last10 = Grabowski | first10 = Patricia Grabowski | authorlink10 = Patricia Grabowski|date=Jan 2021|title=Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198960/|journal=Journal of Clinical Medicine|language=en|volume=10|issue=11|pages=2420|doi=10.3390/jcm10112420|pmc=PMC8198960|pmid=34072494|access-date=|quote=|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198960/ (Full text)] | ||
*2020, A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors<ref name="Wirth2020a">{{Cite journal|last=Wirth| first = Klaus | author-link=Klaus Wirth | last2 = Scheibenbogen | first2=Carmen|author-link2=Carmen Scheibenbogen|date=2020-06-01|title=A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors|url=https://www.sciencedirect.com/science/article/pii/S1568997220300823|journal=Autoimmunity Reviews|language=en|volume=19|issue=6|pages=102527|doi=10.1016/j.autrev.2020.102527|issn=1568-9972}}</ref> - [https://doi.org/10.1016/j.autrev.2020.102527 (Full text)] | *2020, A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors<ref name="Wirth2020a">{{Cite journal|last=Wirth| first = Klaus | author-link=Klaus Wirth | last2 = Scheibenbogen | first2=Carmen|author-link2=Carmen Scheibenbogen|date=2020-06-01|title=A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors|url=https://www.sciencedirect.com/science/article/pii/S1568997220300823|journal=Autoimmunity Reviews|language=en|volume=19|issue=6|pages=102527|doi=10.1016/j.autrev.2020.102527|issn=1568-9972}}</ref> - [https://doi.org/10.1016/j.autrev.2020.102527 (Full text)] | ||
Revision as of 01:26, December 1, 2022
Prof Dr Klaus Wirth and Prof Dr Carmen Scheibenbogen
Theory[edit | edit source]
Hypothesis[edit | edit source]
Endothelial dysfunction is proposed to be key to ME/CFS, which is regarded as a neurovascular disease.[1][2][3]
Evidence[edit | edit source]
Treatment[edit | edit source]
Self-administered Immunoglobulin G (IgG) is a proposed treatment, with a proof of concept trial completed in 2021.[4]
Notable studies[edit | edit source]
- 2021, An attempt to explain the neurological symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[3] - (Full text)
- 2021, Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[2] - (Full text)
- 2021, Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study[4] - (Full text)
- 2020, A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors[1] - (Full text)
[edit | edit source]
- 2012, Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls[5] - (Full text)
- 2011, Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome[6] - (Abstract)
- 2009, Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects[7] - (Abstract)
See also[edit | edit source]
- Endothelial dysfunction
- Beta 2-adrenergic receptor/ß2-adrenergic receptor (ß2AdR)
- Alpha 2-adrenergic receptors/α2-adrenergic receptors (a2AdR)
- Klaus Wirth
- Carmen Scheibenbogen
Learn more[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 Wirth, Klaus; Scheibenbogen, Carmen (June 1, 2020). "A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors". Autoimmunity Reviews. 19 (6): 102527. doi:10.1016/j.autrev.2020.102527. ISSN 1568-9972.
- ↑ 2.0 2.1 Wirth, Klaus J.; Scheibenbogen, Carmen (April 21, 2021). "Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". Journal of Translational Medicine. 19 (1): 162. doi:10.1186/s12967-021-02833-2. ISSN 1479-5876. PMC 8058748. PMID 33882940.
- ↑ 3.0 3.1 Wirth, Klaus J.; Scheibenbogen, Carmen; Paul, Friedemann (November 22, 2021). "An attempt to explain the neurological symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Journal of Translational Medicine. 19 (1): 471. doi:10.1186/s12967-021-03143-3. ISSN 1479-5876. PMC 8607226. PMID 34809664.
- ↑ 4.0 4.1 Scheibenbogen, Carmen; Sotzny, Franziska; Hartwig, Jelka; Bauer, Sandra; Freitag, Helma; Wittke, Kirsten; Doehner, Wolfram; Scherbakov, Nadja; Loebel, Madlen; Grabowski, Patricia Grabowski (January 2021). "Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study". Journal of Clinical Medicine. 10 (11): 2420. doi:10.3390/jcm10112420. PMC 8198960. PMID 34072494.
- ↑ White, Andrea T; Light, Alan R; Hughen, Ronald W; VanHaitsma, Timothy A; Light, Kathleen C (December 30, 2011). "Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls". Psychosom Med. 74 (1): 46-54. doi:10.1097/PSY.0b013e31824152ed. PMID 22210239.
- ↑ Light, Alan R; Bateman, Lucinda; Jo, Daehyun; Hughen, Ronald W; Vanhaitsma, TA; White, Andrea T; Light, Kathleen C (July 13, 2011). "Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome". J Intern Med. 271 (1): 64-81. doi:10.1111/j.1365-2796.2011.02405.x. PMID 21615807.
- ↑ Light, Alan R; White, Andrea T; Hughen, Ronald W; Light, Kathleen C (July 31, 2009). "Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects". J Pain. 10 (10): 1099-112. doi:10.1016/j.jpain.2009.06.003. PMID 19647494.
